Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Yang Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4441-5614; OpenAlex author ID A5005502519. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
22
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 3 papers · 2024: 3 papers · 2025: 1 paper

Papers 12

  1. TREM2 Depletion in Pancreatic Cancer Elicits Pathogenic Inflammation and Accelerates Tumor Progression via Enriching IL-1β+ Macrophages. Last author DOI 10.1053/j.gastro.2025.01.244↗
  2. Loss of p53 and SMAD4 induces adenosquamous subtype pancreatic cancer in the absence of an oncogenic KRAS mutation. Last author DOI 10.1016/j.xcrm.2024.101711↗
  3. Genetic Deletion of Galectin-3 Inhibits Pancreatic Cancer Progression and Enhances the Efficacy of Immunotherapy. Last author DOI 10.1053/j.gastro.2024.03.007↗
  4. Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. Co-author DOI 10.1126/science.adh4567↗
  5. Elimination of oncogenic KRAS in genetic mouse models eradicates pancreatic cancer by inducing FAS-dependent apoptosis by CD8+ T cells. Co-author DOI 10.1016/j.devcel.2023.07.025↗
  6. Anxiolytics cause anxiety in pancreatic cancer. Co-author DOI 10.1016/j.trecan.2023.09.005↗
  7. Single-Cell Analysis Differentiates the Effects of p53 Mutation and p53 Loss on Cell Compositions of Oncogenic Kras-Driven Pancreatic Cancer. Last author DOI 10.3390/cells12222614↗
  8. Oncogenic collagen I homotrimers from cancer cells bind to α3β1 integrin and impact tumor microbiome and immunity to promote pancreatic cancer. Co-author DOI 10.1016/j.ccell.2022.06.011↗
  9. Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer. First author DOI 10.1158/2159-8290.cd-20-1484↗
  10. Type I collagen deletion in αSMA+ myofibroblasts augments immune suppression and accelerates progression of pancreatic cancer. Co-author DOI 10.1016/j.ccell.2021.02.007↗
  11. Dual reporter genetic mouse models of pancreatic cancer identify an epithelial-to-mesenchymal transition-independent metastasis program. Co-author DOI 10.15252/emmm.201809085↗
  12. Phase I trial of M2ES, a novel polyethylene glycosylated recombinant human endostatin, plus gemcitabine in advanced pancreatic cancer. Co-author DOI 10.3892/mco.2014.271↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Anirban Maitra · 5 shared papers, 2023–2025 · strength 1.24
  2. Daowei Yang · 4 shared papers, 2023–2025 · strength 1.01
  3. Xinlei Sun · 4 shared papers, 2023–2025 · strength 1.01
  4. Huamin Wang · 5 shared papers, 2021–2024 · strength 0.89
  5. Raghu Kalluri · 6 shared papers, 2018–2024 · strength 0.83
  6. Ignacio Ivan Wistuba Oyarzun · 3 shared papers, 2024–2025 · strength 0.70
  7. Kathleen M. McAndrews · 4 shared papers, 2022–2024 · strength 0.61
  8. Krishnan K. Mahadevan · 3 shared papers, 2022–2024 · strength 0.48
  9. Sujuan Yang · 3 shared papers, 2021–2022 · strength 0.40
  10. Julienne L. Carstens · 2 shared papers, 2018–2022 · strength 0.21
  11. Hua Wang · 1 shared paper, 2024 · strength 0.21
  12. Hua Wang · 1 shared paper, 2024 · strength 0.21
  13. Haoqiang Ying · 1 shared paper, 2023 · strength 0.15
  14. Ronald Anthony Depinho · 1 shared paper, 2023 · strength 0.15
  15. Jiha Kim · 1 shared paper, 2021 · strength 0.14
  16. Xiaofeng Zheng · 1 shared paper, 2022 · strength 0.13
  17. Huamin Wang · 1 shared paper, 2022 · strength 0.13
  18. Xiaofeng Zheng · 1 shared paper, 2018 · strength 0.09
  19. Dieter Saur · 1 shared paper, 2018 · strength 0.09
  20. Yongzhang Luo · 1 shared paper, 2014 · strength 0.05
  21. Yiqi Du · 1 shared paper, 2014 · strength 0.05
  22. Zhaoshen Li · 1 shared paper, 2014 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.